Loss of TACSTD2 promoted squamous cell carcinoma progression and resistance through attenuating chemotherapeutic reagent-induced apoptosis, implying that TACSTD2 could be used as a marker for pathological grading of SCC (Wang et al. 2014). Here, TACSTD2 is linked to squamous cell carcinoma.